Opsona Appoints Dr Martin Welschof as CEO and Conor Dalton as Director of Finance
2012-02-09
February 9th, 2012, Dublin, Ireland - Opsona Therapeutics, the innate immune drug development company, today announced that it has appointed two experienced biopharm executives to complement its management team.
Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company’s Board of Directors
2012-01-03
- Accera, Inc., announced today that Holger Kunze has been appointed to the position of Chief Executive Officer and as a member of the company's Board of Directors (BoD). Concurrently, Sven Thormahlen, Ph.D., has also been appointed as a member of Accera's BoD.
TOPCRYO™, up in the air with LSG Sky Chefs Germany
2011-11-22
- CRYOLOG with TOPCRYOTM, a microbiological Time Temperature Integrator, is involved in a process of quality insurance and traceability with the German company, LSG Sky Chefs Germany, a worldwide recognized provider of best-in-class products in airline catering. This tool enables LSG Sky Chefs Germany to safeguard cold chain monitoring in real time and in this way, to preserve foodstuffs during long-haul flights between Europe, America and Asia.
Sino-UK companies announce TB vaccine partnership deal
2011-10-17
- ImmunoBiology Ltd, is pleased to announce the signing of an initial cooperation agreement with LIBP, a subsidiary company under Sinopharm's biological products division - CNBG (China National Biotech Group).
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
2011-10-12
- "Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012. Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.
